Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The disclosure states that Panmure Gordon (UK) Limited, as an exempt principal trader, has made purchases and sales of Allergy Therapeutics' 0.1p ordinary shares. The disclosure provides details of the number of securities bought and sold, as well as the highest and lowest prices per unit paid or received.

The disclosure does not mention any cash-settled derivative transactions or stock-settled derivative transactions, including options, related to Allergy Therapeutics' securities. It also states that there are no indemnity or option arrangements, agreements, or understandings between Panmure Gordon (UK) Limited and any party to the offer or any person acting in concert with a party to the offer.

The disclosure was made on October 16, 2023, and the contact person for further information is Freddie Wooding at Panmure Gordon (UK) Limited.

No further information about Allergy Therapeutics or its operations is provided in this news release.